Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression
- 18 May 2017
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (10)
Abstract
Advanced cancer induces fundamental changes in metabolism and promotes cardiac atrophy and heart failure. We discovered systemic insulin deficiency in cachectic cancer patients. Similarly, mice with advanced B16F10 melanoma (B16F10-TM) or colon 26 carcinoma (C26-TM) displayed decreased systemic insulin associated with marked cardiac atrophy, metabolic impairment, and function. B16F10 and C26 tumors decrease systemic insulin via high glucose consumption, lowering pancreatic insulin production and producing insulin-degrading enzyme. As tumor cells consume glucose in an insulin-independent manner, they shift glucose away from cardiomyocytes. Since cardiomyocytes in both tumor models remained insulin responsive, low-dose insulin supplementation by subcutaneous implantation of insulin-releasing pellets improved cardiac glucose uptake, atrophy, and function, with no adverse side effects. In addition, by redirecting glucose to the heart in addition to other organs, the systemic insulin treatment lowered glucose usage by the tumor and thereby decreased tumor growth and volume. Insulin corrected the cancer-induced reduction in cardiac Akt activation and the subsequent overactivation of the proteasome and autophagy. Thus, cancer-induced systemic insulin depletion contributes to cardiac wasting and failure and may promote tumor growth. Low-dose insulin supplementation attenuates these processes and may be supportive in cardio-oncologic treatment concepts.Keywords
This publication has 38 references indexed in Scilit:
- Prevention of liver cancer cachexia-induced cardiac wasting and heart failureEuropean Heart Journal, 2013
- Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of CardiomyocytesCirculation Research, 2013
- The role of triglyceride lipases in cancer associated cachexiaTrends in Molecular Medicine, 2013
- MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathyJournal of Clinical Investigation, 2013
- The role of insulin resistance in the development of muscle wasting during cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Cachexia as a major underestimated and unmet medical need: facts and numbersJournal of Cachexia, Sarcopenia and Muscle, 2010
- Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitusAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Metabolic changes in cancer cachexia — first of two partsClinical Nutrition, 1997
- Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocolsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997